# Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

> **NCT02303821** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 141 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Dexamethasone
- **DRUG:** Mitoxantrone
- **DRUG:** PEG-asparaginase
- **DRUG:** Vincristine
- **DRUG:** Intrathecal (IT) Methotrexate
- **DRUG:** Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)
- **DRUG:** 6-Mercaptopurine
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Daunorubicin

## Key facts

- **NCT ID:** NCT02303821
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-16
- **Primary completion:** 2024-06-28
- **Final completion:** 2024-06-28
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303821, "Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02303821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*